Quantcast
Channel: WN.com - Articles related to Actelion to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia (Actelion Ltd)
Viewing all articles
Browse latest Browse all 480

Axovant Sciences Announces Presentations and Sponsored Symposium at the 2016 Alzheimer's Association International Conference (Axovant Sciences Ltd)

$
0
0
(Source: Axovant Sciences Ltd) Axovant Sciences Announces Presentations and Sponsored Symposium at the 2016 Alzheimer's Association International Conference HAMILTON, Bermuda, July 18, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, announced today that the company will host a symposium and make four poster presentations at the 2016 Alzheimer's Association International Conference (AAIC) being held in Toronto July 24-28. 'Our presence at this year's AAIC highlights our progress towards building a leading pipeline of potential treatments for patients with dementia,' said Vivek Ramaswamy, CEO of...

Viewing all articles
Browse latest Browse all 480

Trending Articles